StockData
Kiniksa Pharmaceuticals International, plc logo

Kiniksa Pharmaceuticals International, plc (KNSA) stock

KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Oct 27, 2026Score 14/30692% above fair value
$92.24−5.32 (-5.45%)

Close on Oct 30, 2026Market cap $14.39BP/E 95.1Yield –

Earnings

Kiniksa Pharmaceuticals International's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 23, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$286.00M
+58.1% on a year earlier
EPS, Q3 FY2026
–
$0.23 a year earlier
Latest guidance
Raised
Oct 27, 2026 · 3 items

Quarterly results

Revenue and earnings per share from each of Kiniksa Pharmaceuticals International's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Feb 23, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Oct 27, 2026before the open$286.00M+58.1%–Release
Q2 FY2026ended Jun 30, 2026Jul 28, 2026before the open$243.60M+55.4%–Release
Q1 FY2026ended Mar 31, 2026Apr 28, 2026before the open$214.30M+55.5%–Release
Q4 FY2025ended Dec 31, 2025Feb 24, 2026before the open$202.10M+65.0%–Release
Q3 FY2025ended Sep 30, 2025Oct 28, 2025before the open$180.90M+61.2%$0.23Release
Q2 FY2025ended Jun 30, 2025Jul 29, 2025before the open$156.80M+44.4%$0.23Release
Q1 FY2025ended Mar 31, 2025Apr 29, 2025before the open$137.80M+72.5%$0.11Release
Q4 FY2024ended Dec 31, 2024Feb 25, 2025before the open$122.50M+46.9%-$0.12Release
Q3 FY2024ended Sep 30, 2024Oct 29, 2024before the open$112.20M+67.5%-$0.18Release
Q2 FY2024ended Jun 30, 2024Jul 23, 2024before the open$108.60M+51.9%–Release
Q1 FY2024ended Mar 31, 2024Apr 23, 2024before the open$79.90M+65.4%-$0.25Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Kiniksa Pharmaceuticals International's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
ARCALYST net product revenueFY2026$1.05B – $1.05B$980.00M – $995.00MRaisedOct 27, 2026
ARCALYST net product revenueFY2026$930.00M – $945.00M$900.00M – $920.00MRaisedApr 28, 2026
R&D expensesFY2026$160.00M – $170.00M–NewOct 27, 2026
SG&A expensesFY2026$270.00M – $280.00M–RaisedOct 27, 2026

Guidance vs results

The last range Kiniksa Pharmaceuticals International gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$670.00M – $675.00M$677.60MΣ4QAbove range
Q4 FY2021Revenue$16.00M – $17.00M$18.70MAbove range

Guidance history

Every forecast Kiniksa Pharmaceuticals International put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Oct 27, 2026SG&A expensesFY2026$270.00M – $280.00MRaised
Oct 27, 2026R&D expensesFY2026$160.00M – $170.00MNew
Oct 27, 2026ARCALYST net product revenueFY2026$1.05B – $1.05BRaised
Jul 28, 2026ARCALYST net product revenueFY2026$980.00M – $995.00MRaised
Apr 28, 2026ARCALYST net product revenueFY2026$930.00M – $945.00MRaised
Feb 24, 2026ARCALYST net product revenueFY2026$900.00M – $920.00MNew
Jan 12, 2026ARCALYST net product revenueFY2026$900.00M – $920.00MNew
Oct 28, 2025ARCALYST net product revenueFY2025$670.00M – $675.00MRaised
Jul 29, 2025ARCALYST net product revenueFY2025$625.00M – $640.00MNew
Apr 29, 2025ARCALYST net product revenueFY2025$590.00M – $605.00MRaised
Feb 25, 2025ARCALYST net product revenueFY2025$560.00M – $580.00MReaffirmed
Jan 13, 2025ARCALYST net product revenueFY2025$560.00M – $580.00MNew
Oct 29, 2024ARCALYST net product revenueFY2024$410.00M – $420.00MRaised
Jul 23, 2024ARCALYST net product revenueFY2024$405.00M – $415.00MRaised
Apr 23, 2024ARCALYST net product revenueFY2024$370.00M – $390.00MRaised
Feb 28, 2024ARCALYST net product revenueFY2024$360.00M – $380.00MNew
Oct 31, 2023ARCALYST net product revenueFY2023$220.00M – $230.00MReaffirmed
Jul 25, 2023ARCALYST net product revenueFY2023$220.00M – $230.00MRaised
May 2, 2023ARCALYST net product revenueFY2023$200.00M – $215.00MRaised
Feb 28, 2023ARCALYST net product revenueFY2023$190.00M – $205.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Kiniksa Pharmaceuticals International filed with the SEC as exhibits to Form 8-K or 6-K

  1. Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution
    Results
  2. Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution
    Results
  3. Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution
    Results
  4. Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution
    Results
  5. Kiniksa Pharmaceuticals Provides Corporate Update
    Results
  6. Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution
    Results
  7. 8-K exhibit EX-99.1
    Update
  8. Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution
    Results
  9. Announces Trial Design of Planned Phase 2/3 Clinical
    Update
  10. PK - Modeling and Dose Simulations for KPL - 387 Phase 2/3 RP Study 22 Target Concentration Pharmacokinetic modeling of KPL - 387 at the anticipated therapeutic dose supports the monthly dose paradigm
    Update
  11. Reports First Quarter 2025 Financial Results and Recent Portfolio Execution
    Results
  12. Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution
    Results
  13. Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance
    Results
  14. Kiniksa Pharmaceuticals Reports Third Quarter
    Results
  15. Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution
    Results